AstraZeneca Restarts MEK Inhibitor In Singapore Research Pact
This article was originally published in The Pink Sheet Daily
Liver-cancer partnership includes failed melanoma drug.
You may also be interested in...
Firms enrolling patients for further trials of the drug candidate in ovarian cancer, hepatocellular and biliary tract carconomas.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.